Page 37 - GP Fall Final 2017
P. 37
References for Treatment for Melanoma and MRONJ
A Case Study with an Introduction to Tafinlar, Mekinist, and Xgeva
®
A Review of Melanoma and MRONJ, page 28
1. http://www.uptodate.com/contents/melanoma-treatment-advanced-or-metastatic-melanoma-beyond-the-basics. Last access
June 26, 2017.
2. Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta–analysis.
Eur J Cancer. 2017 Jun 14; 81:106-115. Doi: 10.1016/j.ejca.2017.05.015.
3. Queirolo P, Picasso V, Spagnolo F. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic mel-
anoma. Cancer Treat Rev. 2015 Jun; 41 (6):519-26. Doi: 10.1016/j.ctrv. 2015.04.010.
4. Falchook GS, Long GV et al. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib. Clin
Cancer Res. 2014 Sep 1:20(17): 4449-58. doi: 10.1158/1078-0432.CCR-14-0887. Epub 2014 Jun 23.
5. Kim KB, Kefford R, Pavlick AC et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with meta-
static BRAF–mutant cutaneous melanoma previously treated with or without a BRAF inhibitor J Clin Oncol. 2013 Feb
1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 17.
6. Uyanne J, Calhoun CC, Le AD. Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin North Am. 2014 Apr; 58(2):
369-84. doi: 10.1016/j.cden.2013.12.006.
7. Green W. Denosumab (Prolia) Injection: A New Approach to the Treatment of Women with Postmenopausal Osteoporosis.
Pharmacy and Therapeutics. 2010; 35(10):553-559.
8. De Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Drame M, Trenque T. Adjudication of osteonecrosis of the jaw I
phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol. 2017 May : 73(5):517-523.
doi:10.1007/s00228-017-2210-x.
9. Boquete-Castro A, Gomez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and
osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res. 2016 Mar;
27(3):367-75. doi:10.1111/cir.12556. Epub 2015 Feb 2.
10. https://www.cancer.org/cancer/melanoma-skin-cancer/treating.html. Last access 06/26/2017.
11. Siin Kim, Hyung Tae Kim, Hae Sun Suh. Combination therapy of BRAF inhibitors for advanced melanoma with BRAF
V600 mutation: a systematic review and meta-analysis.
Journal of Dermatological Treatment Vol. 0, Iss, OO.
12. Rollason V, Lavarrier A, Mac Donald LC, Walsh T, Tramer MR, Vogt-Ferrier NB. Interventions for treating bisphospho-
nate-related osteonecrosis of the jaw (BRONJ).
Cochrane Database Syst Rev. 2016 Feb 26; 2:CD008455. doi: 10.1002/14651858.CD008455.pub2.
13. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Rya F. American Association of Oral and
Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg.
2014 Oct; 72(10): 1938-56.
14. Hayashida S et al. Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and
the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis.
J Bone Miner Res. 2017 June 6. doi: 10.1002/jbmr.3191.
15. Gaudin E, et al. Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a
systematic review and meta-analysis. J Clin Periodontol. 2015 Oct;42 (10):922-32. doi: 10.1111/jcpe.12455. Epub 2015 Nov 3.
